When was Reglagene founded?

Reglagene was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is Reglagene located?

Reglagene is headquartered in Tucson, United States.

How many employees does Reglagene have?

As of Aug 31, 2026, the latest employee count at Reglagene is 10.

Is Reglagene a funded company?

Reglagene is a funded company, having raised a total of $7.65M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 19, 2018.

When was the latest funding round of Reglagene?

Reglagene's latest funding was a $***** Conventional Debt round on May 16, 2024, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $6.45B in funding in 2026 to date.

Where does Reglagene rank among its competitors?

Reglagene ranks 1059th amongst 3037 active competitors, of which 1007 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Reglagene?

Reglagene's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Reglagene - 2026 Company Profile, Funding & Competitors

Company Details

Developer of drugs for treating cancer. It offers small-molecule drugs that can cross the blood-brain barrier and targets diseases like glioblastoma (aggressive brain cancer) and metastatic brain tumor. It offers RGN6024 an Oral (pill-based) treatment that enter the brain and attack tumors.

Key Metrics

Founded Year

2016

Location

Tucson, United States

Stage

Series A

Total Funding

$7.65M in 6 rounds

Latest Funding Round

Conventional Debt, May 16, 2024, $*****

Investors

Desert Angels & 6 more

Ranked

1059^th among 3037 active competitors

Employee Count

10 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 796 more

View Reglagene's full profile

Reglagene is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Reglagene, Inc CIN: 830978720 , United States, Active		-	-	-

Reglagene has raised a total funding of $7.65M over 6 rounds. Its first funding round was on Sep 19, 2018. Reglagene has 7 institutional investors.

Here is the list of recent funding rounds of Reglagene:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 16, 2024	9101869	Conventional Debt	2382957	3820490	1215137	9182202
Dec 19, 2023	5978618	Series A	1899244	4268040	2725115	TCA Venture Group
May 16, 2023	5539150	Seed	3053118	4284478	7523447	Tech Coast Angels

Access funding benchmarks and valuations. Sign up today!

View details of Reglagene's funding rounds and investors

Reglagene's employee count trend

Reglagene has 10 employees as of Aug 26. Here is Reglagene's employee count trend over the years:

Uncover Reglagene's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Reglagene include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Reglagene, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
1059th	Reglagene 2016, Tucson (United States), Series A	Developer of drugs for treating cancer	$7.65M	Tech Coast Angels, Desert Angels & 5 others	39/100